Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Tango Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$30.94

+1.12 (+3.76%)

B 77Pipeline Score Undervalued Biotech · Commercial
Market Cap
2.93 B
EPS
-0.82
P/E Ratio
-
Value Trade
28.44 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    -

  • R&D Expenses

    33.53 M

  • Operating CF

    -44.36 M

  • Total Assets

    435.79 M

  • Total Liabilities

    44.29 M

  • Equity

    391.51 M

  • D/E Ratio

    12,345

-12.38 %
Week
-27.71 %
1 Month
65.49 %
3 Month
134.8 %
6 Month
80.71 %
5 Year
104.86 %
All Time
Cash Data
Healthy

  • Cash Position

    379.84 M

  • Monthly Burn

    14.79 M

  • Runway

    24.8 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
9.96 M
52 Week Range
1.91 - 28.41
% held by Insiders
26.7 %
% held by Institutions
99.69 %
Enterprise Value
2.58 B
Total Shares
144.24 M
Short %
25.97 %
Float Shares
128.95 M
Company Description
HQ: 201 BROOKLINE AVENUE, BOSTON, ...
Employees:137
https://www.tangotx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1/2 data readout example
TNG462 Pancreatic cancer — monotherapy (intended registrational population)
Phase 1/2
—
-
-
TNG462 Pancreatic cancer — monotherapy (intended registrational population)
Phase 1/2
—
-
-
TNG462 Pancreatic cancer — monotherapy (intended registrational population)
Phase 1/2
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B77
Pipeline Score
$25.9B
Pipeline Value
Undervalued
Valuation Signal
54
Drugs Scored
8.8x
rNPV / MCap
Top 97%
Small Cap
(rank 28 of 905)
Percentile Rank
Tango Therapeutics, Inc. holds a solid B-grade pipeline (77/100), with $39.8B risk-adjusted pipeline value, led by Perindopril-indapamide in Diabetes Mellitus, Type 2 (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Perindopril-indapamide
Small molecule		Diabetes Mellitus, Type 2Phase 3NCT0014592558% $15.0B COMPLETED 11,140 - -Mar 1, 2008 -Apr 11, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
TNG462
MTAP-de pancreatic cancer,lung cancer
Phase 1/2
2025-08-06
TNG462
MTAP-de pancreatic cancer,lung cancer
Phase 1/2
2025-08-06
TNG462
MTAP-de pancreatic cancer,lung cancer
Phase 1/2
2025-08-06
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TNGX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
TNGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TNGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TNGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
TNGX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
TNGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Tango Therapeutics, Inc. (TNGX) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How TNGX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Genetic Mutations #1 of 4 PHASE 1 TNG462 + RMC-9805 + RMC-6236 + mFOLFIRINOX + gemcitabine/nab-paclitaxel
ANL MYGN KTTA
—0.82 LEADER
Cholangiocarcinoma #4 of 24 PHASE 3 Ivosidenib
AZN JAZZ LLY
$0.62B 0 CONTENDER
Brain Tumors #5 of 44 PHASE 3 Vorasidenib
NVCR JAZZ DAWN
$3.55B 0.71 CONTENDER
Genetic Disorders #5 of 8 PHASE 1 TNG462 + RMC-9805 + RMC-6236 + mFOLFIRINOX + gemcitabine/nab-paclitaxel
TAK RYTM SABS
$7.95B 0.82 CONTENDER
Myelodysplastic Syndromes #12 of 33 PHASE 3 Ivosidenib + Azacitidine
BMY ABBV TAK
$2.5B 0 FOLLOWER
Epilepsy #12 of 15 PHASE 1 S230815- Starting dose A + S230815- Dose B + S230815- Dose C + S230815- Dose D
XENE PRAX RAPP
$12.0B 0 FOLLOWER
Thyroid Cancer #12 of 12 PHASE 1 S241656 + FOLFOX6/FOLFOX7 + FOLFIRI + Cetuximab + Panitumumab + Gemcitabine + Nab-paclitaxel
LLY NVS EXEL
$4.2B 0 FOLLOWER
Leukemia #17 of 64 PHASE 3 AG-120 + Azacitidine
AMGN MRK LLY
$4.28B 0 CONTENDER
Gastric Cancer #19 of 49 PHASE 2 Trifluridine/Tipiracil + Oxaliplatin + FOLFOX regimen + Nivolumab
AZN ONC JAZZ
$6.74B 0 FOLLOWER
Esophageal Cancer #22 of 39 PHASE 2 Liposomal Irinotecan + Carboplatin + Capecitabine + Oxaliplatin + 5-fluorouracil + Leucovorin
AZN MRK ONC
$1.85B 0 FOLLOWER
Colorectal Cancer #23 of 82 PHASE 3 Trifluridine/tipiracil + Capecitabine + Bevacizumab experimental + Bevacizumab control
ABBV BMY MRK
$7.68B 0 FOLLOWER
Pancreatic Cancer #29 of 72 PHASE 1 TNG462 + RMC-9805 + RMC-6236 + mFOLFIRINOX + gemcitabine/nab-paclitaxel
RVMD RCUS AZN
$3.7B 0.82 FOLLOWER
Non-Small Cell Lung Cancer #32 of 88 PHASE 1 S095018 + S095024 + S095029 + S095018 Recommended Dose Expansion + S095024 RDE + S095029 RDE + Cemiplimab
MRK AZN RVMD
$28.1B 0.78 FOLLOWER
Lung Cancer #35 of 78 PHASE 1 TNG456 + abemaciclib
MRK GILD AMGN
$28.1B 0.78 FOLLOWER
Breast Cancer #56 of 94 PHASE 2 trifluridine/tipiracil
AZN MRK LLY
$10.85B 0 FOLLOWER